A new approach to predicting human hepatic clearance of CYP3A4 substrates using monkey pharmacokinetic data

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Xenobiotica; the fate of foreign compounds in biological systems

• Publication date

  2013-04-02

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.3109/00498254.2012.733831PMID 23153054
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Running Title Page Running title : Cytochromes P 450 detection in cynomolgus monkey liver *

  2011influential reference
• Genetic Variants of CYP3A4 and CYP3A5 in Cynomolgus and Rhesus Macaques

  2010influential reference
• Prediction of Human Metabolic Clearance from In Vitro Systems: Retrospective Analysis and Prospective View

  2010cited by this paper
• Alprazolam as an In Vivo Probe for Studying Induction of CYP3A in Cynomolgus Monkeys

  2010cited by this paper
• Use of intrinsic clearance for prediction of human hepatic clearance

  2010influential reference
• A Comparison of Pharmacokinetics between Humans and Monkeys

  2010cited by this paper
• Prediction of Human Pharmacokinetics From Preclinical Information: Comparative Accuracy of Quantitative Prediction Approaches

  2009influential reference
• Methodological uncertainty in quantitative prediction of human hepatic clearance from in vitro experimental systems.

  2009cited by this paper
• Human clearance prediction: shifting the paradigm

  2009influential reference
• Characterization of cynomolgus monkey cytochrome P450 (CYP) cDNAs: is CYP2C76 the only monkey-specific CYP gene responsible for species differences in drug metabolism?

  2007influential reference
• Prediction of in vivo drug clearance from in vitro data. I: Impact of inter-individual variability

  2006cited by this paper
• Prediction of metabolic drug clearance in humans: In vitro–in vivo extrapolation vs allometric scaling

  2006cited by this paper
• Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human

  2005cited by this paper
• Kinetics and Dynamics of Intravenous Adinazolam, N‐Desmethyl Adinazolam, and Alprazolam in Healthy Volunteers

  2005cited by this paper
• DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS

  2004cited by this paper
• A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. II. Volume of distribution and mean residence time.

  2004cited by this paper
• A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance.

  2004cited by this paper
• Comparative Single-Dose Pharmacokinetics of Clonazepam following Intravenous, Intramuscular and Oral Administration to Healthy Volunteers

  2003cited by this paper
• Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys, and humans

  1997influential reference
• The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data.

  1997cited by this paper
• Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data.

  1997cited by this paper
• Interspecies scaling: predicting clearance of drugs in humans. Three different approaches.

  1996cited by this paper
• Oral first‐pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A‐mediated metabolism

  1996cited by this paper
• Factors affecting the absolute bioavailability of nifedipine.

  1995cited by this paper
• Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance.

  1994cited by this paper
• Physiological Parameters in Laboratory Animals and Humans

  1993influential reference
• Clinical Pharmacokinetics of Alprazolam

  1993cited by this paper
• Molecular cloning of monkey liver cytochrome P-450 cDNAs: similarity of the primary sequences to human cytochromes P-450.

  1992influential reference
• Quinidine kinetics after a single oral dose in relation to the sparteine oxidation polymorphism in man.

  1990cited by this paper
• Bioavailability and pharmacokinetics of nifedipine administered by different routes in healthy volunteers.

  1989cited by this paper
• Clinical Pharmacokinetics of Verapamil, Nifedipine and Diltiazem

  1986cited by this paper
• Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm.

  1984cited by this paper
• Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics

  1982cited by this paper
• Absolute quinidine bioavailability

  1976cited by this paper
• Pharmacokinetics of the anticonvulsant drug clonazepam evaluated from single oral and intravenous doses and by repeated oral administration

  1975cited by this paper

• In vitro–in vivo extrapolation of metabolic clearance using human liver microsomes: factors showing variability and their normalization

  2020cites this paper
• Evaluation of the inhibition of chlorophenols towards human cytochrome P450 3A4 and differences among various species.

  2020cites this paper
• Transporter–enzyme interplay and the hepatic drug clearance: what have we learned so far?

  2020cites this paper
• Differences in nonclinical pharmacokinetics between species and prediction of human pharmacokinetics of TAK‐272 (SCO‐272), a novel orally active renin inhibitor

  2018influential citation
• Comprehensive evaluation of liver microsomal cytochrome P450 3A (CYP3A) inhibition: comparison of cynomolgus monkey and human

  2017cites this paper
• Effects of paeoniflorin on the activities and mRNA expression of rat CYP1A2, CYP2C11 and CYP3A1 enzymes in vivo

  2017cites this paper
• Comparison of predictability for human pharmacokinetics parameters among monkeys, rats, and chimeric mice with humanised liver

  2017influential citation
• Prediction of inter-individual variability on the pharmacokinetics of CYP1A2 substrates in non-smoking healthy volunteers.

  2016cites this paper
• Species differences and substrate specificity of CYP3A heteroactivation by efavirenz

  2015cites this paper
• A Useful Model Capable of Predicting the Clearance of Cytochrome P450 3A4 (CYP3A4) Substrates in Humans: Validity of CYP3A4 Transgenic Mice Lacking Their Own Cyp3a Enzymes

  2014cites this paper
• Dogs and monkeys in preclinical drug development: the challenge of reducing and replacing

  2013cites this paper